Catalyst
Slingshot members are tracking this event:
NTLA in vivo Hepatitis B Virus (HBV) program by Intellia, based on CRISPR/Cas9 genetic editing system, set for HBV animal trials in 2017
- Source Link:
- http://seekingalpha.com/filing/3460363
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 01, 2018
Occurred Source:
http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-quarter-2018-financial
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Hbv, Crispr-cas9, Gene-editing, Animal Trials
